Evolution of the Average Target: Protara Therapeutics, Inc.

Evolution of the Average Target - Protara Therapeutics, Inc.

Evolution of the Target Price: Protara Therapeutics, Inc.

Evolution of the Target Price - Protara Therapeutics, Inc.

Changes in Analyst Recommendations: Protara Therapeutics, Inc.

cb6e2671529e.i0FqiCL2-MlsR6SjWef_w2mX-Dm0mChvAO27-xydCjI.wXFcw1W3vfEqKuvUKImdoRCuqmjb3Ro8aZ3utE_6bQXjCgzxaqfOpCUj9Q~c1b03d9a346fef9800684e64082fc912
05-20 Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating MT
03-04 JPMorgan Initiates Protara Therapeutics at Overweight MT
01-07 Piper Sandler Initiates Protara Therapeutics at Overweight MT
25-05-22 Jones Initiates Protara Therapeutics at Buy With $21 Price Target MT
25-04-16 Scotiabank Initiates Protara Therapeutics at Sector Outperform With $12 Price Target MT
25-03-14 Cantor Fitzgerald Initiates Coverage on Protara Therapeutics With Overweight Rating MT
24-08-12 Oppenheimer Adjusts Protara Therapeutics' PT to $25 From $30, Keeps Outperform Rating MT
24-04-22 Oppenheimer Adjusts Protara Therapeutics Price Target to $30 From $26 MT
23-11-06 Oppenheimer Adjusts Protara Therapeutics Price Target to $26 From $30, Maintains Outperform Rating MT
23-07-10 Guggenheim Assumes Protara Therapeutics at Buy With $22 Price Target MT
22-08-10 HC Wainwright Cuts Protara Therapeutics' Price Target to $23 From $30, Maintains Buy Rating MT
22-05-11 Oppenheimer Adjusts Protara Therapeutics Price Target to $26 From $32, Maintains Outperform Rating MT
22-05-09 HC Wainwright Lowers Protara Therapeutics Price Target to $30 From $40, Buy Rating Kept MT
22-03-14 Oppenheimer Adjusts Protara Therapeutics Price Target to $32 From $34, Maintains Outperform Rating MT
21-11-08 Oppenheimer Adjusts Price Target on Protara Therapeutics to $34 from $32, Keeps Outperform Rating MT
21-08-30 Protara Therapeutics : BofA Securities Starts Protara Therapeutics at Buy With $15 Price Target MT
21-06-04 Protara Therapeutics : HC Wainwright Starts Protara Therapeutics at Buy With $40 Price Target MT
21-04-26 Protara Therapeutics : Oppenheimer Adjusts Protara Therapeutics PT to $32 From $43, Maintains Outperform Rating MT
21-02-17 Protara Therapeutics : Oppenheimer Initiates Coverage on Protara Therapeutics With Outperform Rating, $43 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+932.7%
+41.72%
+26.36%
+10.61%
+10.61%
+16.9%
+37.16%
+42.61%
-17.48%
+30.19%
Average +113.14%
Weighted average by Cap. +23.05%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.515USD
Average target price
25.71USD
Spread / Average Target
+922.44%
High Price Target
30.00USD
Spread / Highest target
+1,092.84%
Low Price Target
20.00USD
Spread / Lowest Target
+695.23%

Analyst Consensus Detail

Analyst consensus - Protara Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Protara Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Protara Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. TARA Stock
  4. Consensus Protara Therapeutics, Inc.